|
|
 Previous Article | Table of Contents | Next Article 
Blood, 1 March 2002, Vol. 99, No. 5, pp. 1825-1832
TRANSPLANTATION
Flt3 ligand therapy for recipients of allogeneic bone marrow
transplants expands host CD8 + dendritic cells and
reduces experimental acute graft-versus-host disease
Takanori Teshima,
Pavan Reddy,
Kathleen P. Lowler,
Mark A. KuKuruga,
Chen Liu,
Kenneth R. Cooke, and
James L. M. Ferrara
From the Departments of Internal Medicine and
Pediatrics, University of Michigan Cancer Center, Ann Arbor; and the
Department of Pathology, Immunology, and Laboratory Medicine,
University of Florida, Gainesville.
Recent evidence suggests that dendritic cells (DCs) can regulate
and amplify immune responses. Flt3 ligand (FL)-derived DC function was
tested as a stimulator of allogeneic lymphocytes in vitro and in vivo.
Treatment of mice with FL dramatically expanded DC number, but DCs
isolated from FL-treated mice (FL DCs) were poor stimulators of
allogeneic T-cell responses in vitro. Further activation of FL DCs did
not restore their stimulatory ability, and FL DCs did not suppress the
stimulation of the allogeneic T cells by normal DCs. FL treatment
significantly increased the CD8 + DC subset, which
appeared to be the reason for their poor stimulatory capacity. These
observations were confirmed in vivo using a mouse model of acute
graft-versus-host disease (GVHD) wherein host DCs play a critical role.
FL treatment of recipients before allogeneic bone marrow
transplantation dramatically suppressed donor T-cell responses to host
antigens, thereby reducing GVHD mortality (P < .01).
These data represent a novel strategy that alters host DCs and reduces
acute GVHD.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. G. Manz
Flt3L, DCs, and NTregs: team contra GVHD?
Blood,
June 18, 2009;
113(25):
6267 - 6268.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. K. Swee, N. Bosco, B. Malissen, R. Ceredig, and A. Rolink
Expansion of peripheral naturally occurring T regulatory cells by Fms-like tyrosine kinase 3 ligand treatment
Blood,
June 18, 2009;
113(25):
6277 - 6287.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Koyama, D. Hashimoto, K. Aoyama, K.-i. Matsuoka, K. Karube, H. Niiro, M. Harada, M. Tanimoto, K. Akashi, and T. Teshima
Plasmacytoid dendritic cells prime alloreactive T cells to mediate graft-versus-host disease as antigen-presenting cells
Blood,
February 26, 2009;
113(9):
2088 - 2095.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Banovic, K. A. Markey, R. D. Kuns, S. D. Olver, N. C. Raffelt, A. L. Don, M. A. Degli-Esposti, C. R. Engwerda, K. P. A. MacDonald, and G. R. Hill
Graft-versus-Host Disease Prevents the Maturation of Plasmacytoid Dendritic Cells
J. Immunol.,
January 15, 2009;
182(2):
912 - 920.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Chakraverty and M. Sykes
The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia
Blood,
July 1, 2007;
110(1):
9 - 17.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Sakoda, D. Hashimoto, S. Asakura, K. Takeuchi, M. Harada, M. Tanimoto, and T. Teshima
Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease
Blood,
February 15, 2007;
109(4):
1756 - 1764.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. R Blazar and W. J Murphy
Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD)
Phil Trans R Soc B,
September 29, 2005;
360(1461):
1747 - 1767.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. F. Fagnoni, B. Oliviero, G. Giorgiani, P. De Stefano, A. Deho, C. Zibera, N. Gibelli, R. Maccario, G. Da Prada, M. Zecca, et al.
Reconstitution dynamics of plasmacytoid and myeloid dendritic cell precursors after allogeneic myeloablative hematopoietic stem cell transplantation
Blood,
July 1, 2004;
104(1):
281 - 289.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. A. Duffner, Y. Maeda, K. R. Cooke, P. Reddy, R. Ordemann, C. Liu, J. L. M. Ferrara, and T. Teshima
Host Dendritic Cells Alone Are Sufficient to Initiate Acute Graft-versus-Host Disease
J. Immunol.,
June 15, 2004;
172(12):
7393 - 7398.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Chklovskaia, P. Nowbakht, C. Nissen, A. Gratwohl, M. Bargetzi, and A. Wodnar-Filipowicz
Reconstitution of dendritic and natural killer-cell subsets after allogeneic stem cell transplantation: effects of endogenous flt3 ligand
Blood,
May 15, 2004;
103(10):
3860 - 3868.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Teshima, P. Reddy, C. Liu, D. Williams, K. R. Cooke, and J. L. M. Ferrara
Impaired thymic negative selection causes autoimmune graft-versus-host disease
Blood,
July 15, 2003;
102(2):
429 - 435.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Ichiba, T. Teshima, R. Kuick, D. E. Misek, C. Liu, Y. Takada, Y. Maeda, P. Reddy, D. L. Williams, S. M. Hanash, et al.
Early changes in gene expression profiles of hepatic GVHD uncovered by oligonucleotide microarrays
Blood,
July 15, 2003;
102(2):
763 - 771.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. P. A. MacDonald, V. Rowe, C. Filippich, R. Thomas, A. D. Clouston, J. K. Welply, D. N. J. Hart, J. L. M. Ferrara, and G. R. Hill
Donor pretreatment with progenipoietin-1 is superior to granulocyte colony-stimulating factor in preventing graft-versus-host disease after allogeneic stem cell transplantation
Blood,
March 1, 2003;
101(5):
2033 - 2042.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
